Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?

Harsha Prasada Lashkari*, Donna Lancaster, Ayad Atra, Michael P. Champion, Mary M. Taj

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    17 Citations (Scopus)

    Abstract

    Severe hyperlipidaemia with asparaginase therapy is rare. We report six cases, four of which developed significant problems with severe hyperlipidaemia during induction therapy for ALL and lymphoblastic lymphoma. The median triglyceride level was 22.3 mmol/L and the median cholesterol level was 12.3 mmol/L. None of the patients showed signs or symptoms of pancreatitis. Three children were re-exposed with Peg asparaginase, and one with Erwinia asparaginase, without recurrence of hyperlipidaemia or other symptoms. These cases highlight the dilemma in managing such rare cases of symptomatic hypertriglyceridaemia secondary to asparaginase and steroid therapy.
    Original languageEnglish
    Pages (from-to)571-575
    Number of pages5
    JournalInternational Journal of Hematology
    Volume94
    Issue number6
    DOIs
    Publication statusPublished - Dec 2011

    Keywords

    • Hypertriglyceridaemia
    • Hypercholesterolaemia
    • Hyperlipidaemia
    • Asparaginase
    • Acute lymphoblastic leukaemia (ALL)
    • Lymphoblastic lymphoma
    • Children
    • HYPERLIPIDEMIC PANCREATITIS
    • LIPID ABNORMALITIES
    • CHILDREN
    • TRANSIENT

    Fingerprint

    Dive into the research topics of 'Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?'. Together they form a unique fingerprint.

    Cite this